222 related articles for article (PubMed ID: 37445707)
1. Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.
Ji L; Waduge P; Wu Y; Huang C; Kaur A; Oliveira P; Tian H; Zhang J; Stout JT; Weng CY; Webster KA; Li W
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445707
[TBL] [Abstract][Full Text] [Related]
2. Neurovascular regulation in diabetic retinopathy and emerging therapies.
Ji L; Tian H; Webster KA; Li W
Cell Mol Life Sci; 2021 Aug; 78(16):5977-5985. PubMed ID: 34230991
[TBL] [Abstract][Full Text] [Related]
3. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.
LeBlanc ME; Wang W; Chen X; Caberoy NB; Guo F; Shen C; Ji Y; Tian H; Wang H; Chen R; Li W
J Exp Med; 2017 Apr; 214(4):1029-1047. PubMed ID: 28330905
[TBL] [Abstract][Full Text] [Related]
4. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.
Ji L; Waduge P; Hao L; Kaur A; Wan W; Wu Y; Tian H; Zhang J; Webster KA; Li W
FASEB J; 2022 Jan; 36(1):e22106. PubMed ID: 34918375
[TBL] [Abstract][Full Text] [Related]
5. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy.
Dai C; Waduge P; Ji L; Huang C; He Y; Tian H; Zuniga-Sanchez E; Bhatt A; Pang IH; Su G; Webster KA; Li W
Cell Mol Life Sci; 2022 Jan; 79(1):63. PubMed ID: 35006382
[TBL] [Abstract][Full Text] [Related]
6. Secretogranin III: a diabetic retinopathy-selective angiogenic factor.
Li W; Webster KA; LeBlanc ME; Tian H
Cell Mol Life Sci; 2018 Feb; 75(4):635-647. PubMed ID: 28856381
[TBL] [Abstract][Full Text] [Related]
7. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
LeBlanc ME; Wang W; Ji Y; Tian H; Liu D; Zhang X; Li W
Exp Eye Res; 2019 Apr; 181():120-126. PubMed ID: 30633921
[TBL] [Abstract][Full Text] [Related]
8. Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.
Ji L; Waduge P; Wan W; Tian H; Li J; Zhang J; Chen R; Li W
FEBS J; 2022 Jun; 289(12):3521-3534. PubMed ID: 35038348
[TBL] [Abstract][Full Text] [Related]
9. Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.
He Y; Tian H; Dai C; Wen R; Li X; Webster KA; Li W
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008775
[TBL] [Abstract][Full Text] [Related]
10. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.
Tang F; LeBlanc ME; Wang W; Liang D; Chen P; Chou TH; Tian H; Li W
Angiogenesis; 2019 Aug; 22(3):369-382. PubMed ID: 30644010
[TBL] [Abstract][Full Text] [Related]
11. Α-Melanocyte-Stimulating Hormone Protects Early Diabetic Retina from Blood-Retinal Barrier Breakdown and Vascular Leakage via MC4R.
Cai S; Yang Q; Hou M; Han Q; Zhang H; Wang J; Qi C; Bo Q; Ru Y; Yang W; Gu Z; Wei R; Cao Y; Li X; Zhang Y
Cell Physiol Biochem; 2018; 45(2):505-522. PubMed ID: 29402864
[TBL] [Abstract][Full Text] [Related]
12. Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.
Wang J; Xu X; Elliott MH; Zhu M; Le YZ
Diabetes; 2010 Sep; 59(9):2297-305. PubMed ID: 20530741
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy.
Dai C; Tian H; Bhatt A; Su G; Webster KA; Li W
Front Biosci (Landmark Ed); 2022 Apr; 27(4):130. PubMed ID: 35468689
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of streptozotocin-induced diabetic retinopathy with low molecular weight fucoidan via inhibition of vascular endothelial growth factor.
Yang W; Yu X; Zhang Q; Lu Q; Wang J; Cui W; Zheng Y; Wang X; Luo D
Exp Eye Res; 2013 Oct; 115():96-105. PubMed ID: 23810809
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor-A
Ved N; Hulse RP; Bestall SM; Donaldson LF; Bainbridge JW; Bates DO
Clin Sci (Lond); 2017 Jun; 131(12):1225-1243. PubMed ID: 28341661
[TBL] [Abstract][Full Text] [Related]
16. Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.
Huang C; Ji L; Kaur A; Tian H; Waduge P; Webster KA; Li W
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509549
[TBL] [Abstract][Full Text] [Related]
17. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells.
Lin M; Chen Y; Jin J; Hu Y; Zhou KK; Zhu M; Le YZ; Ge J; Johnson RS; Ma JX
Diabetologia; 2011 Jun; 54(6):1554-66. PubMed ID: 21360191
[TBL] [Abstract][Full Text] [Related]
18. Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy.
Kim JH; Kim JH; Yu YS; Cho CS; Kim KW
J Cereb Blood Flow Metab; 2009 Mar; 29(3):621-8. PubMed ID: 19107135
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin-induced vascular hyperpermeability through tight junction disruption in diabetic retina.
Someya H; Ito M; Nishio Y; Sato T; Harimoto K; Takeuchi M
Exp Eye Res; 2022 Jul; 220():109094. PubMed ID: 35490836
[TBL] [Abstract][Full Text] [Related]
20. Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.
Dai C; Xiao J; Wang C; Li W; Su G
J Mol Med (Berl); 2022 Jun; 100(6):817-828. PubMed ID: 35394143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
